Here’s me taking a swing at translating a complex pharmaceutical brief, dense with technical language and clinical detail, into warm, human-facing copy. The brief was for Allervia™, a leukotriene receptor antagonist (yes, I had to Google it too), and the goal was to reframe allergic rhinitis as a systemic immune condition, not just a seasonal nuisance. I loved the challenge of turning all that deep science into something real people could connect with—clear, non-jargony, and still medically accurate.

Brief: Allervia™ (azelukast) is a once-daily oral leukotriene receptor antagonist indicated for the treatment of allergic rhinitis in adults. It blocks the CysLT₁ receptor to inhibit the inflammatory effects of leukotriene D₄, reducing nasal congestion, sneezing, and other allergy symptoms. By targeting the allergic response upstream—before histamine release—Allervia provides broader control than traditional antihistamines. It is non-sedating, reaches peak plasma levels in 2 hours, and is metabolized hepatically via CYP3A4 and CYP2C9.

Campaign Objective: Drive awareness and patient-initiated conversations about Allervia™ as a prescription-grade escalation for moderate-to-severe allergy sufferers who remain symptomatic despite OTC antihistamines.

Shift perception of allergic rhinitis from a “minor annoyance” to a chronic, quality-of-life-disrupting immune condition that requires systemic treatment—not symptomatic patchwork.

Target Audience: Adults 30–55 with a multi-year history of seasonal or year-round allergic rhinitis, self-managed via OTCs. Sufferers experience:
• Symptom breakthrough (congestion, sneezing, fatigue)
• Reduced daytime productivity or sleep
• Medication stacking (antihistamines + decongestants)
• Growing frustration and openness to Rx solutions